# Protara Therapeutics Inc. (TARA)

Source: https://www.quantisnow.com/company/TARA
Generated: 2026-11-16T23:13:27.949Z

- Ticker: TARA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2014
- SEC CIK: 0001359931
- Website: protaratx.com

## About

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

## Latest TARA news and filings

- 2026-11-16 17:58 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Protara Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-protara-therapeutics-inc-6793555)
- 2026-11-06 13:10 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Protara Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-protara-therapeutics-inc-6778113)
- 2026-11-06 13:05 UTC [SEC Form 8-K] [Protara Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/protara-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6778102)
- 2026-11-06 13:00 UTC [Earnings] [Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update](https://www.quantisnow.com/insight/protara-therapeutics-announces-third-quarter-2026-financial-results-and-provides-6778060)
- 2026-10-15 12:00 UTC [Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support](https://www.quantisnow.com/insight/protara-therapeutics-completes-enrollment-of-the-phase-2b-open-label-dose-6747275)
- 2026-09-08 20:05 UTC [Conference Announcement] [Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference](https://www.quantisnow.com/insight/protara-therapeutics-to-present-at-the-hc-wainwright-28th-annual-6708203)
- 2026-08-13 16:47 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Protara Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-protara-therapeutics-inc-6679899)
- 2026-08-11 20:15 UTC [SEC Form S-8] [SEC Form S-8 filed by Protara Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-protara-therapeutics-inc-6675914)
- 2026-08-11 12:10 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Protara Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-protara-therapeutics-inc-6675052)
- 2026-08-11 12:05 UTC [SEC Form 8-K] [Protara Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/protara-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6675040)
- 2026-08-11 12:00 UTC [Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update](https://www.quantisnow.com/insight/protara-therapeutics-announces-second-quarter-2026-financial-results-and-provides-6674980)
- 2026-07-07 22:42 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Protara Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-protara-therapeutics-inc-6630595)
- 2026-07-01 20:10 UTC [SEC Form 4] [CEO and President Shefferman Jesse gifted 30,000 shares, exercised 215,687 shares at a strike of $1.91 and sold $882,160 worth of shares (215,687 units at $4.09), decreasing direct ownership by 4% to 691,832 units (SEC Form 4)](https://www.quantisnow.com/insight/ceo-and-president-shefferman-jesse-gifted-30000-shares-exercised-215687-6622888)
- 2026-06-29 21:02 UTC [SEC Form 8-K] [Protara Therapeutics Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/protara-therapeutics-inc-filed-sec-form-8-k-leadership-update-6619324)
- 2026-06-16 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Levy Richard S](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-levy-richard-s-6604666)
- 2026-06-16 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Solomon Michael Edward](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-solomon-michael-edward-6604661)
- 2026-06-16 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Smith Cynthia](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-smith-cynthia-6604659)
- 2026-06-16 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Sargen Gregory](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-sargen-gregory-6604652)
- 2026-06-16 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Huang Jane](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-huang-jane-6604651)
- 2026-06-16 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Flannelly Barry P](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-flannelly-barry-p-6604643)
- 2026-06-16 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Garceau Roger](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-garceau-roger-6604641)
- 2026-06-16 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Beshar Luke M](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-beshar-luke-m-6604638)
- 2026-06-15 20:05 UTC [SEC Form 8-K] [Protara Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/protara-therapeutics-inc-filed-sec-form-8-k-submission-of-matters-6602500)
- 2026-06-03 20:55 UTC [SEC Form 4] [Chief Commercial Officer Conkling William covered exercise/tax liability with 6,008 shares, decreasing direct ownership by 8% to 69,992 units (SEC Form 4) to satisfy withholding tax](https://www.quantisnow.com/insight/chief-commercial-officer-conkling-william-covered-exercisetax-liability-with-6008-6587497)
- 2026-05-28 20:30 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Protara Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-protara-therapeutics-inc-6577450)
- 2026-05-26 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Protara Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-protara-therapeutics-inc-6571030)
- 2026-05-20 12:00 UTC [Conference Announcement] [Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA](https://www.quantisnow.com/insight/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-6564323)
- 2026-05-18 12:00 UTC [Conference Announcement] [Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026](https://www.quantisnow.com/insight/protara-therapeutics-to-host-virtual-investor-webinar-to-discuss-tara-002-6559195)
- 2026-05-15 16:39 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Protara Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-protara-therapeutics-inc-6556597)
- 2026-05-15 11:00 UTC [Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC](https://www.quantisnow.com/insight/protara-therapeutics-announces-positive-updated-12-month-data-demonstrating-durable-responses-6555538)
- 2026-05-13 12:10 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Protara Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-protara-therapeutics-inc-6549842)
- 2026-05-13 12:05 UTC [SEC Form 8-K] [Protara Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/protara-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6549820)
- 2026-05-13 12:00 UTC [Conference Announcement] [Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update](https://www.quantisnow.com/insight/protara-therapeutics-announces-first-quarter-2026-financial-results-and-provides-6549769)
- 2026-04-28 20:15 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Protara Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-protara-therapeutics-inc-6518803)
- 2026-04-28 20:05 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Protara Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-protara-therapeutics-inc-6518561)
- 2026-04-27 20:05 UTC [Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting](https://www.quantisnow.com/insight/protara-therapeutics-to-present-updated-interim-12-month-data-from-the-6516252)
- 2026-04-17 20:15 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Protara Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-protara-therapeutics-inc-6504870)
- 2026-04-09 21:25 UTC [SEC Form 4] [SEC Form 4 filed by Zummo Jacqueline](https://www.quantisnow.com/insight/sec-form-4-filed-by-zummo-jacqueline-6495228)
- 2026-04-02 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Zummo Jacqueline](https://www.quantisnow.com/insight/sec-form-4-filed-by-zummo-jacqueline-6484438)
- 2026-03-30 12:00 UTC [SEC Form 8-K] [Protara Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/protara-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6475937)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/TARA
- Earnings history: https://www.quantisnow.com/earnings/TARA
- Dividend history: https://www.quantisnow.com/dividends/TARA
- Insider transactions: https://www.quantisnow.com/insiders/TARA
- Options chain: https://www.quantisnow.com/options/TARA
- SEC 8-K filings only: https://www.quantisnow.com/company/TARA/8-k
- RSS and alerts for TARA: https://www.quantisnow.com/docs/rss-feeds.md
